Back

The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors: pearls from recent trials and surveys Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Elad Maor

Sheba Medical Center, Tel Aviv (Israel)

3 More presentations in this session

Presentation thumbnail
Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
Doctor C. Adamson (Larbert, GB)
Abstract Slides Video
Presentation thumbnail
Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial
Doctor A. Pandey (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Doctor K. Docherty (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors: pearls from recent trials and surveys

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?
thumbnail
Congress Presentation
Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
thumbnail
Congress Presentation
Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources